M42, an integrated tech-enabled healthcare company, has appointed Mazar Masud as senior director for its global corporate communications division.
The company is the product of a 2023 merger between G42, a technology holding group and Mubadala Investment Company, an Abu Dhabi-based global sovereign investor.
The healthcare tech company strives to bridge the gap between the latest health-tech advancements and the clinical outcomes patients receive.
Masud said, “I’m thrilled to be joining M42 as it continues to transform lives and help solve the world’s most critical health challenges.
Masud was previously the managing director of Edelman’s UAE operations. In the 3 years of his tenure there, the agency’s team has trebled in size and revenues increased by 23 per cent in 2023.
Masud hopes to bring his experience from agency work to implement strong communications strategies at M42. “I’ve always relished creating communications strategies that align with business ambitions and goals,” he said.
He also said he looks forward to working in the niches of technology and healthcare, to empower the communities the company operates in.
“In my new role, I’ll focus on the unique task of articulating the integration of AI and tech in healthcare and the disruption of traditional healthcare ecosystems as a positive for people, the industry and the planet.
This is fascinating from a communications point of view and will require engagement and collaboration across markets and local and global stakeholders,” he said.
Masud went on to reflect on the opportunity the new role brings to his professional life. “Change excites me,” he said.
“My new role will provide new learning opportunities and the scope to deeply focus on one business that is delivering positive global impact.
I’ve really bought into the vision at M42 and its potential to transform lives for the better. The stage is set for global expansion and impact, and I’m honoured to not only be a part of this story but also central to telling it to the world.”
The M42 group includes Diaverum, Cleveland Clinic Abu Dhabi, Imperial College London Diabetes Centre and Moorfields Eye Hospital Abu Dhabi, among others.
